Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes

• Published in: Diabetes, obesity & metabolism obesity & metabolism, 2011-10, Vol.13 (10), p.869-879
• Main Authors: Chaudhuri, A., Dandona, P.
• Format: Article
• Language: English
• Subjects: antidiabetic drug; Antidiabetics; Biguanides - pharmacology; cardiovascular disease; Cardiovascular diseases; Cardiovascular Diseases - prevention & control; Clinical trials; Diabetes; Diabetes mellitus; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetic Angiopathies - prevention & control; Dipeptidyl-Peptidase IV Inhibitors - pharmacology; Drug therapy; Dyslipidemia; Glucagon; Glucagon-Like Peptide 1 - analogs & derivatives; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hyperglycemia - complications; Hyperglycemia - drug therapy; Hypoglycemic Agents - pharmacology; Hypoglycemic Agents - therapeutic use; Incretins - pharmacology; Insulin; Insulin - pharmacology; Insulin - therapeutic use; insulin therapy; lipid-lowering therapy; Lipids; Morbidity; Patients; Randomized Controlled Trials as Topic; Sulfonylurea Compounds - pharmacology; Thiazolidinediones; Thiazolidinediones - pharmacology
• ISSN: 1462-8902; 1463-1326
• DOI: 10.1111/j.1463-1326.2011.01423.x

Increased morbidity and mortality risk due to diabetes‐associated cardiovascular diseases is partly associated with hyperglycaemia as well as dyslipidaemia. Pharmacological treatment of diabetic hyperglycaemia involves the use of the older oral antidiabetic drugs [OADs: biguanides, sulphonylureas (SUs), α‐glucosidase inhibitors and thiazolidinediones], insulin (human and analogues) and/or incretin‐based therapies (glucagon‐like peptide‐1 analogues and dipeptidyl peptidase 4 inhibitors). Many of these agents have also been suggested to improve lipid profiles in patients with diabetes. These effects may have benefits on cardiovascular risk beyond glucose‐lowering actions. This review discusses the effects of OADs, insulins and incretin‐based therapies on lipid variables along with the possible mechanisms and clinical implications of these findings. The effects of intensive versus conventional antihyperglycaemic therapy on cardiovascular outcomes and lipid profiles are also discussed. A major conclusion of this review is that agents within the same class of OADs can have different effects on lipid variables and that contrary to the findings in experimental models, insulin has been shown to have beneficial effects on lipid variables in clinical trials. Further studies are needed to understand the precise effect and the mechanisms of these effects of insulin on lipids.